Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aducanumab - Neurimmune Therapeutics

X
Drug Profile

Aducanumab - Neurimmune Therapeutics

Alternative Names: Aducanumab-avwa; ADUHELM; Anti-beta amyloid monoclonal antibody - Biogen/Neurimmune Therapeutics; BART; BIIB 037; NI-10

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurimmune Therapeutics; University of Zurich
  • Developer Neurimmune Therapeutics
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 07 Feb 2024 Phase-III clinical trials in Alzheimer's disease (SC), prior to February 2024 (Neurimmune pipeline, February 2024)
  • 07 Feb 2024 Neurimmune Therapeutics terminates phase III/IV ENVISION trial for Alzheimer's disease in Australia, Belgium, Brazil, Canada, Finland, France, Germany, Italy, Japan, South Korea, Mexico, Poland, Portugal, Spain, Sweden, United Kingdom, United States due to sponsor's decision which was not related to safety (NCT05310071)
  • 31 Jan 2024 Neurimmune Therapeutics terminates collaboration and license agreement with Biogen for Aducanumab for worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top